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ABSTRACT  
 
RATIONALE 
Curcumin analogues are antineoplastic agents, designed based on the structure of the spice 
turmeric with structural modifications aiming at enhancing potency. The goal is to identify the 
common tandem mass spectrometric (MS/MS) behavior of 13 novel curcumin analogues. Such 
knowledge is critical for their biological assessment, including metabolite identification and 
pharmacokinetic evaluation. 
 
METHODS  
Both detection of the protonated molecules [M+H]+ of the synthesized compounds and 
determination of their exact molecular masses were achieved with a hybrid quadrupole 
orthogonal time-of-flight mass spectrometer (QqTOF-MS). Low-energy collision induced 
dissociation (CID)-MS/MS analysis was performed using a triple quadrupole linear ion trap mass 
spectrometer (QqLIT-MS). Both instruments were equipped with an electrospray ionization 
(ESI) source. MS3 and neutral loss experiments were performed using the QqLIT-MS to confirm 
the genesis of the observed product ions.  
  
RESULTS  
Abundant [M+H]+ molecules were formed using the QqTOF-MS hybrid instrument with 
mass accuracies below 6 ppm. CID-MS/MS dissociation studies were centered on the piperidone 
ring of curcumin analogues;twelve common product ions have been identified from the fission of 
the various bonds within the piperidone moiety. There was a tendency for the formation of 
highly conjugated product ions, stabilized via resonance. The variety of the side chain 
substituents at the nitrogen atom resulted in side chain-specific product ions.  
 
CONCLUSIONS 
The ESI-CID-MS/MS analysis of curcumin analogues revealed a common fragmentation 
behavior of all tested compounds, which gave diagnostic product ions identified for each 
molecule. The established MS/MS behavior will be applied to determine metabolic by-products 
of curcumin analogues as well as to develop targeted identification/quantification methods 
within biological extracts.   
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INTRODUCTION 
In the last few decades, the anticancer drug market showed significant growth due to the 
constant and crucial need for more selective, potent and, safe anticancer agents. Natural products 
represent one of the valuable sources for the development of novel anticancer agents.[1, 2] 
Biologically active compounds can either be extracted from its natural source or designed as 
structural analogues for naturally existing compounds.[1, 2] For example, curcumin is a natural 
component of the spice turmeric that showed various biological activities including anticancer, 
anti-inflammatory, antioxidant, and anti-microbial effects.[3, 4] The poor bioavailability of 
curcumin has limited its efficiency as anticancer agent.[5] Consequently, curcumin analogues 
were designed by structural modification of the curcumin molecule to enhance bioavailability 
and potency.[6, 7]  
A number of curcumin analogues showed promising anticancer properties towards different 
cancer cell lines including melanoma and colon and pancreatic cancer cells.[8-11] The evaluated 
curcumin analogues in this study were 3,5-bis(benzylidene)-4-piperidone compounds, containing 
the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore (Scheme 1A) that acts as thiol alkylator and 
responsible for the selective antitumor effect of these compounds.[11-14] For more effective 
antitumor activity, a series of novel curcumin analogues were designed with various substituents 
on the aryl groups and the piperidyl nitrogen atom of the 3,5-bis(benzylidene)-4-piperidone 
(Scheme 1B). The aryl substituents were added to change the steric and hydrophobic properties 
of curcumin analogues in order to enhance their in-vivo use.[14] On the other hand, the N-
substituents were introduced to enhance the drug penetration into the target cells by protecting 
the piperidyl nitrogen atom from ionization at biological pH, since ionized molecules are 
incapable to penetrate the cell membrane.[12] In addition, the presence of N-substituents offers 
additional binding sites to the target cells which may increase the cytotoxicity of the drug 
candidate.[12, 13] 
 
To evaluate the safety and efficiency of the newly designed compounds during preclinical 
and clinical studies, efficient analytical methods are required. Mass spectrometry (MS) is widely 
used in the drug discovery and development process based on its sensitivity, selectivity and high 
throughput capability.[15, 16] MS structurally characterizes the target analytes via accurate mass 
measurements (single stage MS analysis) as well as via collision-induced dissociation tandem 
mass spectrometric (CID-MS/MS) analysis.[17] The establishment of CID-MS/MS fragmentation 
patterns of structurally-related compounds allows confirmation of their molecular structure and 
identification of their diagnostic product ions to be used subsequently for qualitative and 
quantitative analysis. For example, our research group illustrated a universal MS/MS 
dissociation behavior of a series of structurally-related cationic surfactants used as drug delivery 
agents.[18, 19] The data was subsequently used to develop targeted MS-based quantification 
methods that were employed within cellular lysate to assess the uptake and removal of these 
cationic lipids.[20, 21] In fact, the development of a general MS/MS dissociation behavior will 
allow for the prediction of the fragmentation patterns of newly synthesized compounds with 
structural similarities.  
Recently, we investigated the ionization behavior of 13 curcumin analogues (Scheme 1B) 
illustrating a unique ionization mechanism that resulted in the formation of what we proposed to 
be positively charged [M-H]+ ions during single stage matrix assisted laser desorption ionization-
MS (MALDI-MS) and atmospheric pressure photo ionization (APPI)-MS analysis.[22] 
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Conversely, only the expected [M+H]+ species were observed during electrospray (ESI) and 
atmospheric pressure chemical ionization (APCI).[22] In this subsequent study, we are evaluating 
the low-energy CID-ESI-MS/MS fragmentation behavior of the protonated molecules [M+H]+ 
obtained from the curcumin analogues (Scheme 1B). Due to the wide array of structures for 
currently investigated curcumin analogues in the literature,[23-26] our main aim is to create a 
general CID-MS/MS fingerprint that would allow identification of common CID-fragmentation 
patterns among the diverse structures. We identified for the first time a general MS/MS 
dissociation behavior that will allow precise analysis of other structurally-related compounds. In 
addition, our data will facilitate future studies, concerning metabolite identification as well as the 
development of multiple reaction monitoring (MRM) quantification methods.  
 
EXPERIMENTAL 
Materials 
Curcumin analogues were synthesized by using previously reported synthetic methods.[13, 14] 
The compounds are categorized based on the nature of the N-substituent as phosphoramidates, 
secondary amines, mixed amines/amides and, amides (Scheme 1B). 
 
Mass spectrometric analysis 
Single-stage MS analysis 
Stock solutions of each curcumin analogue were prepared to a concentration of 1mg/mL in 
100% acetonitrile (ACN). Each sample was further diluted by 500–1000× prior to single stage 
and tandem MS analysis. Curcumin analogues were analyzed using an AB SCIEX QSTAR® XL 
instrument (Foster City, California), which is a quadrupole time-of-flight hybrid mass 
spectrometer (QqTOF-MS) equipped with ESI source.  
Samples were injected into the QqTOF-MS at flow rate of 10 µL/min using a Harvard 
Syringe Pump. The system was operated in the positive ion mode with an ionspray voltage of 
5000 V, a declustering potential of 40 V and, a focusing potential of 120 V. Exact mass 
measurements of the curcumin analogues were performed using the QqTOF-MS with a two point 
external calibration. External calibration was performed prior to analyzing the curcumin 
analogues. Two singly charged calibration standards were used; Cesium iodide (CsI, purity 
99.9%, [M]+ m/z 132.9055, CAS Number 7789-17-5, Sigma-Aldrich, Oakville, ON, Canada) and 
Sex pheromone inhibitor iPD1 (C39H72N8O11, purity >94%, [M+H]+ m/z 829.5320, CAS 
Number 120116-56-5, Bachem Bioscience Inc., PA, USA).  
 
Tandem mass spectrometric analysis 
Tandem mass spectrometric analysis of curcumin analogues was conducted on the AB 
SCIEX 4000 QTRAP® instrument (Foster City, California), which is a hybrid triple quadrupole–
linear ion trap mass spectrometer (QqLIT-MS). The MS/MS, multi-stage-MS (MS3), enhanced 
product ion scan and, neutral loss scan analysis were performed for each sample to confirm the 
precursor ion’s structure and its fragmentation pathway. MS/MS was also acquired using the 
QqTOF-MS; however, the data was not as informative as minor fragmentation was obtained in 
comparison to the rich MS/MS data obtained by the QqLIT-MS. This is due to the fact that the 
QqLIT-MS allows for the accumulation of ions in the linear ion trap when applying the 
“enhanced” product ion scan. Such capabilities are not possible with the QqTOF-MS instrument.  
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In both instruments, collision induced dissociation (CID) was conducted in the positive ion 
mode with an ionspray voltage of 5500 V, a declustering potential of 40-70 V and, a collision 
energy (CE) of 20-35 V using nitrogen as a collision gas. Parameters of the MS/MS analysis 
were optimized to ensure the formation of the product ions while maintaining the presence of the 
precursor ion.  
 
RESULTS AND DISCUSSION 
Single-stage MS analysis  
The ESI-MS (positive ion mode) full scan analysis of curcumin analogues showed abundant 
protonated molecules, [M+H]+. The exact masses of the curcumin analogues were measured by 
measuring the protonated molecules masses using the ESI-QqTOF-MS, which gave mass 
accuracies of less than 6 ppm mass error (Table 1 in supplementary materials). This confirms the 
molecular structure of tested compounds, particularly when combined with MS/MS analysis, 
detailed below. The ability to achieve such high mass accuracy was attributed to applying 
external calibration of the instrument directly prior to analyzing tested compounds. In fact, such 
results were comparable to recent structural work in which internal calibration was employed 
showing mass accuracy of less than 5 ppm when analyzing cationic surfactants using the QqToF-
MS system. [19]  
 
Tandem mass spectrometric analysis 
The fragmentation behavior of curcumin analogues was evaluated using low-energy collision 
induced dissociation (CID) of ESI-QqLIT-MS in the positive ion mode. All tested curcumin 
analogues have the same backbone structure of 3,5-bis(benzylidene)-4-piperidone (Scheme 1A) 
that showed similar fragmentation behavior with bond cleavage occurring at the piperidone ring 
during the MS/MS analysis. The differences among curcumin analogue structures was based on 
the difference in the substituents of the aryl groups and the piperidyl nitrogen atom of the 3,5-
bis(benzylidene)-4-piperidone (Scheme 1B). Such differences resulted in specific product ions 
during MS/MS analysis that could be used as diagnostic product ions for the qualitative and 
quantitative MS/MS-analysis of these compounds. The side chain of curcumin analogues (N-
substituents) was also dissociated during the low energy CID-MS/MS analysis. However, the 
side chain fragmentation did not follow a general pattern due to the dramatic differences in their 
chemical structures. 
The detailed general fragmentation behavior of curcumin analogues was discussed in two 
sections; 3,5-bis(benzylidene)-4-piperidone fragmentation and side chain fragmentation to 
highlight the common MS/MS pathways among various curcumin analogues. It should be 
emphasized that we are identifying common dissociation behavior among various structures of 
curcumin analogues that can allow for the analysis of other compounds.  
 
3,5-bis(benzylidene)-4-piperidone fragmentation 
The curcumin analogue tagged as NC 2067 will be used as a representative model for all of 
the curcumin analogues. The CID- MS/MS analysis of this compound gave the highest number 
of common product ions, which were generated via the fragmentation of the 3,5-
bis(benzylidene)-4-piperidone moiety. The ESI-QqLIT-MS/MS analysis for the NC2067 showed 
11 product ions (F1-11) (Figure 1). The CID-fragmentation was centered specifically on the 
piperidone ring (highlighted in bold blue in Figure 1A) of the 3,5-bis(benzylidene)-4-piperidone 
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moiety. Accordingly, each detected product ion was formed by breaking the specific bonds of 
that ring illustrated in the structure within Table 1A. Table 1A shows the 12 common product 
ions detected during the MS/MS analysis of the 13 curcumin analogues. On the other hand, 
Table 2A illustrates the observed m/z values of the common product ions during the 
fragmentation of the bis(benzylidene)-4-piperidone moiety of the 13 curcumin analogues with 
NC2067 producing 11 out of the 12 common product ions. 
Initial dissociation of the piperidone ring occurs via a cleavage of the bonds (1 and 3). Two 
mechanisms can occur concurrently producing either the minor product ion observed at m/z 
351.1 (F1) or the highly abundant product ion observed at m/z 117.0 (F3). The proposed two 
mechanisms are shown in Scheme 2 in which the charge is presumably localized on the nitrogen 
atom. The first mechanism involves the neutral loss of C9H8 (116 Da) (Scheme 2A). This occurs 
via electron re-localization (shown by arrows within the structures in Scheme 2A) resulting in 
the species observed at m/z 351.1 where the positive charge is relocalized on the carbon of the 
carbonyl group. However, F1 ion is quickly converted into the more abundant highly conjugated 
stable diagnostic product ion at m/z 349.1 (F2) by losing a hydrogen molecule (Figure 1A).  
The second mechanism involving cleavages of bonds 1 and 3 of the piperidone ring (Scheme 
2B) resulted in the formation of the product ion F3 observed at m/z 117.0. In this mechanism, 
hydrogen rearrangement occurs; however, charge is located on the smaller species while the 
relatively large 350 Da species is eliminated as a cyclized neutral moiety. The F3 ion is one of 
the most abundant product ions that has been detected with all curcumin analogues (Table 2A). 
This could be due to the stable conjugated structure of this small ion that enables it to resist 
additional fragmentation. The mechanism shown in Scheme 2 that includes rearrangement, 
electron movements and cyclization is the driving principle for the formation of the majority of 
the piperidone-driven fragmentation.  
In addition to F3, two other product ions were observed at m/z 131.1 (F4) and 143.1 (F5) by 
breaking the piperidone bonds at (1 and 5) and (1 and 4) respectively (Tables 1A and 2A). 
Similar to F3, both F4 and F5 are small ions with high conjugation within their structures (Figure 
1A).  
The product ion F6 observed at m/z 247.1 is formed through cleavage of bonds (2 and 4), 
followed by a sequential elimination of a carbonyl group CO and methylene CH2 resulting in the 
formation of ions, F7 at m/z 219.1 and F8 at m/z 205.1. It should be noted that the loss of 
methylene group (14 Da) is not expected; however, MS3 experiment showed that F8 at m/z 205.1 
is formed from the product ion F6 at m/z 247.1 (Table 2, Supplementary materials) and the only 
possible pathway for such dissociation (i.e. loss of 14 Da) is via the elimination of methylene 
group. Another sequential fragmentation that was observed in eight curcumin analogues includes 
the formation of the ion designated F9 observed at m/z 259, which in the case of NC2067 was 
formed by breaking bonds (3 and 4) and cyclization (Figure 1A & Tables 1A and 2A). F9 ion 
usually loses a carbonyl group to form another product ion (F10) at m/z 231.1 that in turns losses 
a hydrogen molecule to generate F11 at m/z 229.1. As it can be seen among the majority of 
observed product ions, the dissociation behavior is driven by the formation of highly conjugated 
structures during the CID-MS/MS analysis of curcumin analogues. 
The same fragmentation behavior of the 3,5-bis(benzylidene)-4-piperidone moiety of 
NC2067 was detected with other curcumin analogues (Table 2A). This behavior enables the 
establishment of a general fragmentation pattern for these compounds based on the CID-MS/MS 
of the 3,5-bis(benzylidene)-4-piperidone moiety as shown in Table 2A. However, the number of 
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detected product ions varied between curcumin analogues based on their structural differences. It 
can be speculated that the difference in the substituents of the aryl groups and the piperidyl 
nitrogen atom between curcumin analogues affect the stability of the piperidone ring and make it 
more or less susceptible to dissociation. For example, product ion designated as (F12) was 
detected with few curcumin analogues (not with NC2067) by breaking the piperidone ring bonds 
at (1 and 2). The absence of few product ions within some curcumin analogues could also be due 
to the fast conversion of these product ions into more stable species. For example, in Table 2A, 
the product ion (F10) was not detected with NC2315 curcumin analogue however, the product 
ion (F11) which is generated from (F10) by the loss of hydrogen molecule was detected with this 
compound. This indicates that the product ion (F10) was formed during the fragmentation of 
NC2315 and completely converted into F11. 
To confirm the sequence of the proposed fragmentation (Figure 1A), MS3 analysis was 
performed (Table 2 in supplementary materials). The MS3 experiments of NC2067 illustrated 
that one product ion could be formed from different sources. For example, the product ion 
observed at m/z 143.1 was formed from two other product ions (m/z 259.1 and 247.1) in addition 
to its possible direct formation from the precursor ion. On the other hand, a unique product ion 
has been formed only during the MS/MS analysis of NC2067 (not shown in Table 3) with m/z 
value= 189.1. In fact, MS3 analysis confirmed that this ion is a third generation product ion 
formed from the second generation product ion observed at m/z 349.1 via serial self-explanatory 
dissociation mechanism (Figure 1A).  
In addition to MS3 experiments, neutral loss scans were performed to confirm the precursor 
ion’s structure and the proposed fragmentation pathway. For example, the product ion (F3) was 
proposed to be directly formed by neutral loss of 350 Da from the precursor ion (467.1 Da) 
(Figure 1A). This pathway was confirmed by scanning the neutral loss of 350 Da during the 
MS/MS analysis of the protonated molecule formed from NC2067, and it confirmed that the 
precursor ion at m/z 467.1 was the sole source for the product ion (F3) at m/z 117.0.   
The CID-MS/MS of the protonated molecules of the curcumin analogues possessing 
secondary amines: at m/z 336.1 for NC2453, m/z 396.1 for NC2454, m/z 312.1 for EF24, and m/z 
308.1 for NC2128) partially followed the general pathway presented in Tables 1A and 2A by 
showing mainly the product ions of F3, F4 and F5. The absence of the side chain in these 
compounds may have resulted in the observed variations in their MS/MS dissociation behavior. 
Similar to other compounds, the CID-MS/MS fragmentation of the secondary amine curcumin 
analogues was driven by the cleavage of the piperidone ring, albeit in a different fashion than the 
compounds with side chains (Tables 1B and 2B).  
In Figure 2, the MS/MS spectrum of NC 2128 was used as a representative compound 
showing the direct loss of the carbonyl group from the precursor ion m/z 308.0 via breaking the 1 
and 6 bonds resulting in the product ion F1' observed at m/z 280.0.. The amino group in the 
product ion (F1') is eliminated as ammonia (NH3) during the MS/MS of the curcumin analogue 
NC2128 forming the product ion (F2') at m/z 263.0. This loss is shown in Figure 2A.  
In addition, two product ions, namely  F4' at m/z 107.0 and F5' at 214.1 in case of NC2128 
(Figure 2 and Table 2B) were uniquely generated by the fragmentation of the benzylidene group 
of the 3,5-bis(benzylidene)-4-piperidone moiety via breaking the bonds I and II as shown in 
Table 1B. Curcumin analogues are highly conjugated species that can exist in resonance forms as 
shown in Figure 2A. In effect, bond I is converted from a double bond into a single bond while 
the double bond is located within the piperidone ring. As such, curcumin analogues can be 
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dissociated through the fission of bond I, eliminating a neutral species (201.0 Da), to yield 
product ion ion F4' at m/z 107.0 (Figure 2A). Unlike F4', product ion F5' at m/z 214.1 can 
undergo additional dissociating via the loss of the NH3 group producing F6' at m/z 197.1 which in 
turns loses the carbonyl group forming F7' at m/z 169.1. Similar to F5', in which dissociation 
occurred at bond II, F8' at m/z 201.1 is another product ion that was formed by the cleavage of 
the bond II.  
The loss of the aryl substituent (RH) is one of the common product ions that have been 
detected with the MS/MS analysis of the secondary amines curcumin analogues. In the case of 
NC2128, such a loss constitutes a loss of water producing F9’ at m/z 290.0. There are two 
possible mechanisms that explain the formation of F9’ as presented in Figure 2A. The proposed 
mechanisms are dependent on the site of protonation of the precursor ion that may occur either 
on the basic amino group [which was presumed as the main site of protonation for this molecule] 
or the hydroxyl group of NC2128. In the former case, a cyclic highly conjugated F9’ product ion, 
was proposed (Figure 2A). On the other hand, if the charge was localized on the hydroxyl group 
of NC2128, the loss of water yields the production of F9’ species in which the positive charge is 
localized within the aromatic ring (Figure 2A), enhancing the stability of this ion via resonance. 
The mechanisms governing the formation of other product ions shown in Figure 2A are self-
explanatory such as ions observed at m/z 273.0 and 245.1. The MS3 and neutral loss experiments 
were performed (Table 3 in supplementary materials) to confirm the proposed fragmentation 
pathway as presented in Figure 2A.   
 
Side chain fragmentation 
The side chain dissociation behavior of the tested curcumin analogues was based on the 
structural features of each side chain. In Figure 1A, the side chain fragmentation of NC2067 was 
focused on the amide bond (bond is identified with an arrow in the precursor ion) with the 
neutral loss of the 3,5-bis(benzylidene)-4-piperidone moiety (275 Da), generating the ion of the 
side chain (FI) at m/z = 192.1. Other side chain product ions (FII and FIII) were observed at m/z 
147.1 and 72.0, respectively, as shown in Figure 1A. The MS3 and the neutral loss scan 
experiments were performed to confirm the fragmentation pathway of these ions. For example, 
the product ion (FII) at m/z 147.1 was formed from the ion (FI) at m/z 192.1 and also from (F2) 
at m/z 349.1 (Table 2 in supplementary materials). On the other hand, a neutral loss of 395 Da 
was investigated, confirming the proposed direct formation of the product ion (FIII) at m/z 72 
from the precursor ion (Figure 1A).  
The same fragmentation behavior of the side chain of NC2067 was also observed with other 
curcumin analogues that belong to the amides and mixed amine/amide categories as presented in 
(Table 4A in supplementary materials). The generated (FI) from NC2067 and NC2094 at m/z 
192 and 191 respectively were abundant product ions characteristic to their precursor ions, to 
possibly serve as diagnostic product ions for these compounds. Another abundant (FI) product 
ion was detected at m/z 135 during the MS/MS analysis of NC2144 and NC2138 (Table 4A in 
supplementary materials). However, this ion cannot be used to differentiate between NC2144 
and NC2138 since the structure of the product ions are identical in both cases.  
In the phosphoramidate curcumin analogues (Scheme 1), the side chain product ions were 
formed in different fashion than the previously discussed compounds (Table 4B in 
supplementary materials). In this group, the product ion (Fi) was formed via the loss of the 
ethylene group from the side chain of the precursor ion, followed by sequential loss of other 
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ethylene group to form the (Fii) ion. The dissociation was ended by the neutral loss of water 
molecule forming (Fiii) ion (Table 4B in supplementary materials). In addition to the proposed 
side chain fragmentation, another structure was proposed for the (Fi) ion through the neutral loss 
of carbonyl group from the 3,5-bis(benzylidene)-4-piperidone moiety instead of side chain 
fragmentation. 
 
The protonation site 
The presence of different substituents on the aryl groups and the piperidyl nitrogen atom of 
curcumin analogues resulted in change in the basic properties of each atom in the structures of 
these compounds. It was not conclusive to determine which atom will show high electron density 
and will be able to accept a proton during the single stage positive ion mode MS analysis. 
However, during CID-MS/MS analysis of curcumin analogues such as NC2311 with precursor 
ion [M+H]+ = 412.1, a minor product ion at m/z 394.1 was observed (data not shown). This 
product ion was a result of direct loss of water molecule (18 Da), indicating that the precursor 
ion has a hydroxyl group which is only possible if the protonation site was the oxygen atom as 
presented in Scheme 3. This observation was detected with NC2311, NC2314 and NC2315 
proving that oxygen atoms are possible site for protonation during the ionization of curcumin 
analogues. 
CONCLUSION 
In this work, exact mass measurement confirmed the elemental composition of the 13 novel 
antineoplastic curcumin analogues with mass accuracy <6 ppm. The QqLIT-MS/MS 
fragmentation pattern was established for each compound confirming its chemical structure and 
revealing its diagnostic product ions that are characteristic for each compound. The established 
fragmentation patterns were confirmed via MS3 and neutral loss experiments that confirmed the 
proposed chemical structure of the product ions and the fragmentation pathway. A similar 
fragmentation behavior was observed among all tested curcumin analogues that mainly centered 
on the cleavage of the piperidone ring. However, such behavior was affected by the different 
substituents on curcumin analogues. The purpose of this work is to develop a general 
fragmentation behavior of all tested curcumin analogues which is illustrated in Tables 1A and 
2A. 
The similarity in the fragmentation behaviors among various structures allowed for the 
establishment of a general fragmentation pattern for these compounds, illustrated in Tables 1 and 
2.  This will be beneficial in future quantitative and qualitative analysis. Such MS-fingerprint 
pattern can be used for the identification of these compounds or other compounds belonging to 
the 3,5-bis(benzylidene)-4-piperidone structural family. In addition, the use of the diagnostic 
product ions in quantification of curcumin analogues via multiple-reaction monitoring (MRM) 
analysis will ensure selectivity especially in the presence of complex matrices during preclinical 
and clinical studies.   
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Scheme 1. Schematic representation of the 3,5-bis(benzylidene)-4-piperidones with the N-substituent as 
a side chain, (the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore is highlighted in bold red) (A). 
Structures and monoisotopic masses of the novel antineoplastic curcumin analogues categorized 
by the N-substituent into four structural families: phosphoramidates, secondary amines, mixed 
amines/amides and amides (B). 
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Figure 1. The proposed fragmentation pattern (A) and the ESI-QqLIT-MS/MS spectrum (B) of 
NC2067 (the piperidone ring of NC2067 is highlighted in bold blue and the side chain bond is 
identified with an arrow).  
 
 
A)  General fragmentation scheme of all tested curcumin analogues Product ions Broken Bonds 
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F5 1 & 4 
F6 2 & 4 
F7 1, 2, 4 & 6 
F8 1, 2, 5 & 6 
F9 3 & 4 
F10 1, 3, 4 & 6 
F11 1, 3, 4 & 6 
F12 1& 2 
B) Special fragmentation scheme of secondary amine curcumin analogues Product ions Broken Bonds 
 F1' 1 & 6 
F2' 1, 3, 4 & 6 
F3' 1, 2, 3, 4, 5 & 6 
F4' I 
F5' II 
F6' II, 3 & 4 
F7' II, 1, 3, 4 & 6 
 F8' I, 3 & 4 
F9' R 
Table 1.  The fragmentation sites in the 3,5-bis(benzylidene)-4-piperidone and the corresponding 
product ions during the ESI-MS/MS of the tested curcumin analogues (A). The fragmentation 
sites in the 3,5-bis(benzylidene)-4-piperidone and the corresponding product ions during the ESI-
MS/MS of the secondary amine curcumin analogues (B). 
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Table 2. The product ions of the 3,5-bis(benzylidene)-4-piperidone moiety during the ESI-MS/MS of all tested curcumin analogues 
(A). Special product ions were formed during the ESI-MS/MS of secondary amines curcumin analogues (B).
A) The 3,5-bis(benzylidene)-4-piperidone fragmentation 
Compound Precursor ion P = [M+H]+ 
F1            F2            F3            F4            F5            F6           F7            F8           F9            F10            F11            F12 
(P-C9H8) (F1-H2) (P-N1) (P-N2) (P-N3) (P-N4) (F6-CO) (F7-CH2) (P-N5) (F9-CO) (F10- H2) (P- N6) 
2311 412.2 296 - 117 131 143 247 219 205 259 231 229 308 
2313 472.2 - - 147 161 - 307 - - - - - - 
2314 532.2 - - 177 191 203 - - - 379 - - 368 
2315 592.2 - - 207 221 233 427 - - 439 - 409 398 
2067 467.2 351 349 117 131 143 247 219 205 259 231 229 - 
2081 509.2 - 391 117 - 143 247 219 205 259 231 229 - 
2144 410.2 294 - 117 131 143 247 219 205 259 231 229 - 
2138 410.2 - - 117 131 143 247 219 205 259 231 229 306 
2094 466.2 - - 117 - - 247 219 205 259 231 229 - 
2453 336.2 - - 147 161 173 - - - - - - - 
2454 396.2 - - 177 191 203 - - - 379 - - - 
EF24 312.2 - - 135 149 161 283 - - - - - - 
2128 308.2 - 174 133 147 159 - - - 291 - - - 
B) The fragmentation of secondary amines curcumin analogues 
Compound Precursor ion P = [M+H]+ 
F1'            F2'            F3'            F4'           F5'            F6'           F7' F8' F9'    
(P-CO) (F1'-NH3) (F2'-C2H2) (P-X1) (P-X2) (F5’-NH3) (F6’-CO)  (P-RH)    
2453 336.2 308 291 265 121 228 211 183 215 304    
2454 396.2 368 351 325 151 258 241 213 245 364    
EF24 312.2 284 267 - 109 216 - 171 203 292    
2128 308.2 280 263 237 107 214 197 169 201 290    
 
N1 = C10H4NO +R1+R2+R3+R4+R5   N3 = C9H6N +R1+R2+R3+R4+R5   N5 = NH2+R5 X1 = C12H7NO +R1+R2+R3+R4     
N2 = C10H6N +R1+R2+R3+R4+R5   N4 = CH2N+R5 N6 = C8H4 +R1+R2+R3+R4  X2 = C6H2 +R1+R2+R3+R4     
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Figure 2. The proposed fragmentation pattern (A) and the ESI-QqLIT-MS/MS spectrum (B) of 
NC 2128 secondary amine curcumin analogue 
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Scheme 3. The direct loss of water molecule from the precursor ion of NC2311 (412.1) and the 
formation of a product ion with m/z value at 394.1 
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